

**PATIENT INFORMATION**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg

Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_

Patient Preferred Location: \_\_\_\_\_

&lt;ICD 10 CODE REQUIRED&gt;

**DIAGNOSIS & CLINICAL INFORMATION****ICD 10 Code**

E88.01 Alpha-1-Antitrypsin Deficiency

Other: \_\_\_\_\_

**Prescribing Information**Alpha<sub>1</sub>-Proteinase Inhibitors are **contraindicated** in Immunoglobulin A (IgA) deficient patients with antibodies against IgA and those with a history of anaphylaxis or other severe systemic reaction to Alpha1-PI products.**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.**LAB RESULTS:** Testing to support diagnosis: Alpha-1 antitrypsin (AAT) protein blood testing, genetic testing results, Pulmonary Function Tests, &/or CT scan.**PRESCRIPTION****Pre-Medications**

Acetaminophen: 650 mg PO

Cetirizine: 10 mg PO

Diphenhydramine: 25mg PO

Diphenhydramine: 25mg IVP

Famotidine: 20 mg PO

Methylprednisolone: 125 mg SIVP

Other: \_\_\_\_\_

**ALPHA<sub>1</sub>-PROTEINASE INHIBITOR (Human)****Loading Dose (SELECT ONE)**

Glassia IV: Infuse \_\_\_\_\_ mg/kg (+/- 10%) over at least 30 minutes or at a maximum rate of 0.2 mL/kg/min

Prolastin-C IV: Infuse \_\_\_\_\_ mg/kg (+/- 10%) over at least 30 minutes or at a maximum rate of 0.08 mL/kg/min

Aralast NP IV: Infuse \_\_\_\_\_ mg/kg (+/- 10%) over at least 30 minutes or at a maximum rate of 0.2 mL/kg/min

**Frequency (FILL IN)**

Every \_\_\_\_\_ week(s) for one year

Patient Weight: \_\_\_\_\_ lbs or \_\_\_\_\_ kg

Is the patient on any other disease modifying therapy? **Yes** **No**

If yes, please note therapy and last dose: \_\_\_\_\_

**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.**Comments:**  
\_\_\_\_\_  
\_\_\_\_\_**PRESCRIBER INFORMATION**

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_